TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 568-580

  Ito, R ^a   Tsujihata, Y ^a   Matsuda Nagasumi, K ^a   Mori, I ^a   Negoro, N ^a   Takeuchi, K ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

cell preservation; glycaemic control; GPR40 FFAR1; hyperlipidaemia; insulin secretion; metformin; TAK 875; Zucker diabetic fatty rats

Indexed keywords

CYCLINE; FASIGLIFAM; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; TRANSCRIPTION FACTOR PDX 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DUODENUM; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZUCKER DIABETIC FATTY RAT;

GLYCAEMIC CONTROL; GPR40/FFAR1; HYPERLIPIDAEMIA; INSULIN SECRETION; METFORMIN; TAK-875; ZUCKER DIABETIC FATTY RATS; Β-CELL PRESERVATION;

ANIMALS; BENZOFURANS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLUCAGON; HEMOGLOBIN A, GLYCOSYLATED; HOMEODOMAIN PROTEINS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; METFORMIN; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; TIME FACTORS; TRANS-ACTIVATORS;

EID: 84884539468     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12297     Document Type: Article

References (53)

1. Araki T, Hirayama M, Hiroi S, Kaku K, (2012). GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14: 271-278.
2. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D, (2002). Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes Obes Metab 4: 368-375.
3. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. (2003). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303-11311.
4. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379: 1403-1411.
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC, (2003). Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
6. Charpentier G, (2002). Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 18 (Suppl. 3): S70-S76.
7. Edfalk S, Steneberg P, Edlund H, (2008). Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287.
8. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. (2001). Beta-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 50: 1021-1029.
9. Flodgren E, Olde B, Meidute-Abaraviciene S, Winzell MS, Ahren B, Salehi A, (2007). GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem Biophys Res Commun 354: 240-245.
10. Fu A, Eberhard CE, Screaton RA, (2013). Role of AMPK in pancreatic beta cell function. Mol Cell Endocrinol 366: 127-134.
11. Fujiwara K, Maekawa F, Yada T, (2005). Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289: E670-E677.
12. Giorgino F, Laviola L, Leonardini A, (2005). Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res Clin Pract 68 (Suppl. 1): S22-S29.
13. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE, (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30: 1979-1987.
14. Han SJ, Choi SE, Kang Y, Jung JG, Yi SA, Kim HJ, et al. (2011). Effect of sitagliptin plus metformin on beta-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Res Clin Pract 92: 213-222.
15. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP, (1999). In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 48: 1995-2000.
16. Hundal RS, Inzucchi SE, (2003). Metformin: new understandings, new uses. Drugs 63: 1879-1894.
17. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. (2012). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577-1596.
18. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. (2003). Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176.
19. Jain S, de Azua IR, Lu H, White MF, Guettier JM, Wess J, (2013). Chronic activation of a designer Gq-coupled receptor improves beta cell function. J Clin Invest 123: 1750-1762. doi: 10.1172/JCI66432.
20. Janssen SW, Martens GJ, Sweep CG, Span PN, Verhofstad AA, Hermus AR, (2003). Phlorizin treatment prevents the decrease in plasma insulin levels but not the progressive histopathological changes in the pancreatic islets during aging of Zucker diabetic fatty rats. J Endocrinol Invest 26: 508-515.
21. Kahn SE, (2000). The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108 (Suppl. 6a): 2S-8S.
22. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V, (2008). The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57: 2432-2437.
23. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
24. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, et al. (2007). GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56: 1087-1094.
25. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH, (1994). Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 91: 10878-10882.
26. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, et al. (2011). AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 6: e27270.
27. Lupi R, Del Guerra S, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, et al. (1999). The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 364: 205-209.
28. Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patanè G, et al. (2002). Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 51 (Suppl. 1): S134-S137.
29. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. (2001). Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 24: 489-494.
31. Marchetti P, Del Guerra S, Marselli L, Lupi R, Masini M, Pollera M, et al. (2004). Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 89: 5535-5541.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, (1985). Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
33. Melloul D, (2004). Transcription factors in islet development and physiology: role of PDX-1 in beta-cell function. Ann N Y Acad Sci 1014: 28-37.
34. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H, (2009). Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 157: 415-426.
35. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, et al. (2009). Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58: 1067-1076.
36. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, et al. (2012). Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52: 1007-1016.
37. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, et al. (2010). Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Medicinal. Chem Lett 1: 290-294.
38. Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, et al. (2012). Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G-protein coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent. J Med Chem 55: 3960-3974.
39. Pan QR, Li WH, Wang H, Sun Q, Xiao XH, Brock B, et al. (2009). Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell. Horm Metab Res 41: 799-804.
40. Perfetti R, Hui H, (2004). The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res 36: 804-810.
41. Pratley RE, (2009). Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 10: 503-512.
42. Rafacho A, Ribeiro DL, Boschero AC, Taboga SR, Bosqueiro JR, (2008). Increased pancreatic islet mass is accompanied by activation of the insulin receptor substrate-2/serine-threonine kinase pathway and augmented cyclin D2 protein levels in insulin-resistant rats. Int J Exp Pathol 89: 264-275.
43. Rendell M, (2004). The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64: 1339-1358.
44. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD, (2005). Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 335: 97-104.
45. Sloop KW, Michael MD, Moyers JS, (2005). Glucagon as a target for the treatment of type 2 diabetes. Expert Opin Ther Targets 9: 593-600.
46. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H, (2005). The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1: 245-258.
47. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, et al. (2008). Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211-2219.
48. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, et al. (2011). TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339: 228-237.
49. U.K. Prospective Diabetes Study Group (1995). U.K. prospective diabetes study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44: 1249-1258.
50. Williams-Herman D, Xu L, Teng R, Golm GT, Johnson J, Davies MJ, et al. (2012). Effect of initial combination therapy with sitagliptin and metformin on beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 14: 67-76.
51. Winzell MS, Ahren B, (2007). G-protein-coupled receptors and islet function-implications for treatment of type 2 diabetes. Pharmacol Ther 116: 437-448.
52. Yashiro H, Tsujihata Y, Takeuchi K, Hazama M, Johnson PR, Rorsman P, (2012). The effects of TAK-875, a selective GPR40/FFA1 agonist, on insulin and glucagon in isolated rat and human islets. J Pharmacol Exp Ther 340: 483-489.
53. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, et al. (2011). Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 14: 21-32.